Award
National Institute of Allergy and Infectious Diseases 5R01AI145679-05
Emergence of bedaquiline and clofazimine resistance after interruption of drug-resistant TB therapy in a high HIV prevalence setting
Recipient
Albert Einstein College of Medicine
Award Amount
$723,336.00
Ceiling
$723,336.00
Awarded
December 12, 2024
Identifier
5R01AI145679-05
Research project funded by NIH/NIAID to study drug resistance in tuberculosis treatment interruptions in high HIV prevalence settings, focusing on bedaquiline and clofazimine resistance mechanisms and pharmacokinetics.
Description
This project addresses critical issues in TB treatment, especially in high HIV prevalence settings like South Africa, and aims to inform better management of drug resistance risks during therapy interruptions. It investigates resistance development during treatment interruption, measures plasma and intracellular drug concentrations, uses deep sequencing to identify minority resistant subpopulations, and follows patients for 6 months to assess treatment failure or resistance.